Medicover AB stock analysis
Medicover AB (0RPS) Share Price & Analysis
0RPS Stock Chart & Stats
- Day’s Range
- SEK 266.00 - SEK 267.50
- 52-Week Range
- SEK 179.60 - SEK 284.00
- Previous Close
- SEK 266.50
- Volume
- N/A
- Average Volume (3M)
- 21.64K
- Market Cap
- SEK 40.35B
- Enterprise Value
- SEK 53.10B
- Total Cash (Recent Filing)
- SEK 86.00M
- Total Debt (Recent Filing)
- SEK 1.26B
- Price to Earnings (P/E)
- 40.8
- Beta
- 0.96
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 1.65
- Last Dividend Ex-Date
- Apr 30, 2026
- Dividend Yield
- 0.81%
Bulls Say, Bears Say
Bulls Say
Organic Growth And Margin Expansion
Sustained organic growth alongside repeated margin improvement indicates that Medicover is expanding its operating base while converting revenue into stronger profitability. Continued progress across multiple quarters supports durable earnings development and suggests the business can benefit from scale, pricing and operational discipline.
Strong Cash Generation
Positive and improving operating cash flow provides internal funding for network investment, site development and other strategic priorities. Free cash flow exceeding recent capital spending also gives Medicover greater resilience and supports financial improvement without relying entirely on external financing.
India Divestment And Deleveraging
The planned India exit could materially reshape the group by concentrating resources on core countries while providing substantial proceeds for debt reduction and capital allocation. A debt-free balance sheet would improve financial flexibility, lower risk and strengthen capacity for future growth or consolidation.
Bears Say
Elevated Leverage
Current leverage remains a meaningful constraint despite expected improvement from the India transaction. Debt funding can amplify earnings volatility, increase financial risk and limit flexibility for investment or acquisitions if operating performance weakens or revenue growth remains subdued.
Top-line Softness And Thin Margins
Recent revenue contraction creates pressure on a business whose net profitability remains relatively thin. Even with improving EBIT and net income, weaker top-line momentum could restrict operating leverage, make margin gains harder to sustain and leave less buffer against cost or demand pressures.
Reimbursement And Regional Operating Pressure
Regulatory reimbursement changes and weaker regional membership create structural execution challenges across important operating areas. These pressures may reduce revenue quality or diagnostics profitability over several quarters, while required operational adjustments could delay recovery in affected markets.
Medicover AB News
0RPS FAQ
What was Medicover AB’s price range in the past 12 months?
What is Medicover AB’s market cap?
When is Medicover AB’s upcoming earnings report date?
How were Medicover AB’s earnings last quarter?
Is Medicover AB overvalued?
Does Medicover AB pay dividends?
What is Medicover AB’s EPS estimate?
How many shares outstanding does Medicover AB have?
What happened to Medicover AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medicover AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Medicover AB
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- John Paul Stubbington
- Employees
- 49,000
- Website
- www.medicover.com
- Address
- Riddargatan 12A, Stockholm, AB, 102 46, SE
Medicover AB (0RPS) Earnings & Revenues
0RPS Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Management reported sustained organic growth, seven consecutive quarters of year-on-year margin improvement, stronger profitability, improved leverage, a significant India divestment expected to generate approximately EUR 740 million, and continued expansion in Sports and Wellness and Diagnostics. The company acknowledged several near-term challenges, including German genetics reimbursement reform, softer German Diagnostics activity, slower Romanian membership and hospital performance, FX pressure and temporary revenue effects from site changes and prior pricing decisions. Management repeatedly characterized these issues as manageable or temporary and maintained its targets.
View all GB:0RPS earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 6 | 3 | 1 |
| Moving Averages | 7 | 0 | 5 |








